178 related articles for article (PubMed ID: 34861697)
1. Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo.
Zhang X; Zhang R; Ren C; Xu Y; Wu S; Meng C; Pataer A; Song X; Zhang J; Yao Y; He H; Chen H; Ma W; Wang J; Meric-Bernstam F; Champlin RE; Heymach JV; Rooney CM; Swisher SG; Vaporciyan AA; Roth JA; You MJ; Wang M; Fang B
Blood Adv; 2022 Feb; 6(3):891-901. PubMed ID: 34861697
[TBL] [Abstract][Full Text] [Related]
2. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of duvelisib on Epstein-Barr virus-associated lymphoma cells.
Kawada JI; Ando S; Torii Y; Watanabe T; Sato Y; Ito Y; Kimura H
Cancer Med; 2018 Apr; 7(4):1275-1284. PubMed ID: 29522278
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma.
Siddiquey MN; Nakagawa H; Iwata S; Kanazawa T; Suzuki M; Imadome K; Fujiwara S; Goshima F; Murata T; Kimura H
Cancer Sci; 2014 Jun; 105(6):713-22. PubMed ID: 24712440
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus detection in non-Hodgkin's lymphoma of the oral cavity: an immunocytochemical and in situ hybridization study.
Leong IT; Fernandes BJ; Mock D
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):184-93. PubMed ID: 11505266
[TBL] [Abstract][Full Text] [Related]
6. An HIV protease inhibitor, ritonavir targets the nuclear factor-kappaB and inhibits the tumor growth and infiltration of EBV-positive lymphoblastoid B cells.
Dewan MZ; Tomita M; Katano H; Yamamoto N; Ahmed S; Yamamoto M; Sata T; Mori N; Yamamoto N
Int J Cancer; 2009 Feb; 124(3):622-9. PubMed ID: 18973272
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma.
Pfeffermann LM; Pfirrmann V; Huenecke S; Bremm M; Bonig H; Kvasnicka HM; Klingebiel T; Bader P; Rettinger E
Cytotherapy; 2018 Jun; 20(6):839-850. PubMed ID: 29754771
[TBL] [Abstract][Full Text] [Related]
8. Identification of IgH gene rearrangement and immunophenotype in an animal model of Epstein-Barr virus-associated lymphomas.
Zhang Y; Peng X; Tang Y; Gan X; Wang C; Xie L; Xie X; Gan R; Wu Y
J Med Virol; 2016 Oct; 88(10):1804-13. PubMed ID: 26991077
[TBL] [Abstract][Full Text] [Related]
9. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas.
Nepomuceno RR; Balatoni CE; Natkunam Y; Snow AL; Krams SM; Martinez OM
Cancer Res; 2003 Aug; 63(15):4472-80. PubMed ID: 12907620
[TBL] [Abstract][Full Text] [Related]
10. EBV
Liu H; Xu-Monette ZY; Tang G; Wang W; Kim Y; Yuan J; Li Y; Chen W; Li Y; Fedoriw GY; Zhu F; Fang X; Luedke C; Medeiros LJ; Young KH; Hu S
Histopathology; 2022 Feb; 80(3):575-588. PubMed ID: 34637146
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus latent membrane protein-1 oncogene deletions: correlations with malignancy in Epstein-Barr virus--associated lymphoproliferative disorders and malignant lymphomas.
Kingma DW; Weiss WB; Jaffe ES; Kumar S; Frekko K; Raffeld M
Blood; 1996 Jul; 88(1):242-51. PubMed ID: 8704180
[TBL] [Abstract][Full Text] [Related]
12. Lymphomas driven by Epstein-Barr virus nuclear antigen-1 (EBNA1) are dependant upon Mdm2.
AlQarni S; Al-Sheikh Y; Campbell D; Drotar M; Hannigan A; Boyle S; Herzyk P; Kossenkov A; Armfield K; Jamieson L; Bailo M; Lieberman PM; Tsimbouri P; Wilson JB
Oncogene; 2018 Jul; 37(29):3998-4012. PubMed ID: 29691476
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus-specific T cells for the management of Epstein-Barr virus lymphomas.
Finberg RW
Curr Opin Oncol; 2001 Sep; 13(5):349-53. PubMed ID: 11555711
[TBL] [Abstract][Full Text] [Related]
14. Disparity analysis and prognostic value of pretreatment whole blood Epstein-Barr virus DNA load and Epstein-Barr encoding region status in lymphomas: A retrospective multicenter study in Huaihai Lymphoma Working Group.
Shen Z; Hu L; Yao M; He C; Liu Q; Wang F; Gu W; Wang Y; Dong M; Zhu T; Yin T; Li F; Jin Y; Huang S; Zhang H; Sang W;
Int J Cancer; 2022 Jan; 150(2):327-334. PubMed ID: 34520566
[TBL] [Abstract][Full Text] [Related]
15. mTOR inhibitors induce cell-cycle arrest and inhibit tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells.
Kawada J; Ito Y; Iwata S; Suzuki M; Kawano Y; Kanazawa T; Siddiquey MN; Kimura H
Clin Cancer Res; 2014 Nov; 20(21):5412-22. PubMed ID: 25208880
[TBL] [Abstract][Full Text] [Related]
16. Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
Mentzer SJ; Perrine SP; Faller DV
Transpl Infect Dis; 2001 Sep; 3(3):177-85. PubMed ID: 11493400
[TBL] [Abstract][Full Text] [Related]
17. Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies.
Faller DV; Mentzer SJ; Perrine SP
Curr Opin Oncol; 2001 Sep; 13(5):360-7. PubMed ID: 11555713
[TBL] [Abstract][Full Text] [Related]
18. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.
Kataoka K; Miyoshi H; Sakata S; Dobashi A; Couronné L; Kogure Y; Sato Y; Nishida K; Gion Y; Shiraishi Y; Tanaka H; Chiba K; Watatani Y; Kakiuchi N; Shiozawa Y; Yoshizato T; Yoshida K; Makishima H; Sanada M; Onozawa M; Teshima T; Yoshiki Y; Ishida T; Suzuki K; Shimada K; Tomita A; Kato M; Ota Y; Izutsu K; Demachi-Okamura A; Akatsuka Y; Miyano S; Yoshino T; Gaulard P; Hermine O; Takeuchi K; Ohshima K; Ogawa S
Leukemia; 2019 Jul; 33(7):1687-1699. PubMed ID: 30683910
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms.
Abruzzo LV; Rosales CM; Medeiros LJ; Vega F; Luthra R; Manning JT; Keating MJ; Jones D
Am J Surg Pathol; 2002 May; 26(5):630-6. PubMed ID: 11979093
[TBL] [Abstract][Full Text] [Related]
20. Knockout of Epstein-Barr virus BPLF1 retards B-cell transformation and lymphoma formation in humanized mice.
Whitehurst CB; Li G; Montgomery SA; Montgomery ND; Su L; Pagano JS
mBio; 2015 Oct; 6(5):e01574-15. PubMed ID: 26489865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
